How have the past 5 years of research changed clinical practice in paediatric nephrology?

Stephen D Marks1

  • 1Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London WC1N 3JH, UK. markss2@gosh.nhs.uk

Insights

Paediatric nephrology advances improve diagnosis and management of kidney diseases in children. Evidence-based treatments and renal transplantation reduce morbidity and mortality, enhancing long-term outcomes.

Area of Science:

  • Pediatric Nephrology
  • Genetics and Molecular Biology
  • Renal Medicine

Background:

  • Clinical practice in pediatric nephrology is rapidly advancing, driven by 21st-century research.
  • Management of congenital renal anomalies, urinary tract infections, nephrotic syndrome, and hypertension is increasingly evidence-based.
  • Obesity-related hypertension is a growing focus in primary and secondary care.

Purpose of the Study:

  • To highlight the evolving landscape of pediatric nephrology.
  • To emphasize advancements in diagnosis, treatment, and management of pediatric kidney diseases.
  • To discuss the impact of genetic discoveries and improved therapeutic strategies.

Main Methods:

  • Review of current clinical practices and research in pediatric nephrology.
  • Integration of evidence-based guidelines for managing common pediatric renal conditions.
  • Discussion of emerging diagnostic tools and therapeutic interventions.

Main Results:

  • Improved prenatal diagnosis through molecular and cytogenetic advancements.
  • Effective medical management to delay chronic kidney disease progression and reduce proteinuria.
  • Renal transplantation as the preferred treatment for end-stage renal failure, with dialysis modalities evolving.
  • Advancements in imaging technologies like MRI and CT scans.
  • Focus shifting towards reducing morbidity and preventing long-term complications like atherosclerosis.

Conclusions:

  • Paediatric nephrology is characterized by significant progress in evidence-based management and treatment strategies.
  • Genetic discoveries are enhancing prenatal diagnosis and understanding of kidney diseases.
  • Renal transplantation and evolving dialysis techniques offer improved outcomes for children with end-stage renal failure.
  • Ongoing clinical trials are yielding more effective treatments, reducing disease-related morbidity and drug side effects.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).